Chromatographia

, Volume 62, Issue 3–4, pp 197–201 | Cite as

HPLC Method for Determination of Rosiglitazone in Plasma

Short Communication
First Online:
Received:
Revised:
Accepted:

Abstract

A fast and sensitive high performance liquid chromatography method for quantitative determination of rosiglitazone in human plasma has been developed. The extraction from plasma was performed using solid-phase extraction (SPE) on C4 silica (100 mg) disposable extraction cartridges (DEC). The separation of rosiglitazone and two metabolites was achieved on a Phenomenex® Synergi 4 µm MAX-RP (150 × 4.6 mm) column, protected by a guard column. The mobile phase was 0.01 M ammonium acetate, pH 7.0 - acetonitrile (65:35, v/v). (3S)-3-OH-quinidine was used as internal standard. The analytes were detected using fluorescence detection. The method was validated. The limit of quantitation was 1 ng mL−1 and the detection limit was 0.25 ng mL−1 for rosiglitazone in human plasma. The recovery was 90% for rosiglitazone. Linearity was observed over a range of 1-1000 ng mL−1 (r2=0.9959). The intra- and inter-day precision (C.V.) did not exceed 8.7 %. Applicability of the method was demonstrated by a clinical pharmacokinetic study. A healthy volunteer received in two separate phases 4 mg and 8 mg rosiglitazone maleate as a single oral dose. Plasma concentrations were measured for 24 h in both phases.

Keywords

Column liquid chromatography Solid-phase extraction Clinical pharmacokinetics Rosiglitazone in plasma 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Patel J, Miller E, Patwardhan R (1998) Diabetes 47 Suppl 1:A47Google Scholar
  2. Young PV, Buckle DR, Cantello BBC, Chapman H, Claphan JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KWM, Mossakowska D, Murphy GJ, Cox LR, Smith SA (1998) J Pharmacol Exp Ther 284:751–759PubMedGoogle Scholar
  3. Lehmann JM, Moore LB, Smitholiver TA, Wilkison WO, Wilson TM, Kliewer SA (1995) J Biol Chem 270:12953–12956CrossRefPubMedGoogle Scholar
  4. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD (1996) Endocrinology 137:4189–4195CrossRefPubMedGoogle Scholar
  5. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Bech KD, Moore LB, Kliewer SA, Lehmann JM (1996) J Med Chem 39:665–668CrossRefPubMedGoogle Scholar
  6. Forman BM, Chen J, Evans RM (1996) Peroxisomes:Biology and Role in Toxicology and Disease 804:266–275Google Scholar
  7. Gimble JM, Robinson CE, Wu XY, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC (1996) Mol Pharmacol 50:1087–1094PubMedGoogle Scholar
  8. Tai TAC, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkinson WO, Brown HR, Lehmann JM, Kliewer SA, Morris DC, Graves RA (1996) J Biol Chem 271:29909–29914CrossRefPubMedGoogle Scholar
  9. Tontonoz P, Hu ED, Devine J, Beale EG, Spielgelman BM (1995) Mol Cell Biol 15:351–357PubMedGoogle Scholar
  10. Pearson SL, Cawthorne MA, Claphan JC, Dunmore SJ, Holmes SD, Moore GBT, Smith SA, Tadayyon M (1996) Biochem Biophys Res Comm 229:752–757CrossRefPubMedGoogle Scholar
  11. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J (1996) Embo J 15:5336–5348PubMedGoogle Scholar
  12. Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Brigs MR, Paterniti JR, Fruchart JC, Fievet C, Auwerx J, Staels B (1997) Arterioscler Thromb Vasc Biol 17:1756–1764PubMedGoogle Scholar
  13. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J (1997) J Biol Chem 272:28210–28217CrossRefPubMedGoogle Scholar
  14. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N (1998) J Biol Chem 16710–16714Google Scholar
  15. Henry RR (1997) Endocrinol Metab Clin North Am 26:553–573CrossRefPubMedGoogle Scholar
  16. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, Cowley H (2000) Drug Metab Disp 28:772–780Google Scholar
  17. Baldwin SJ, Clarke SE, Chenery RJ (1999) Br J Clin Pharmacol 48:424–432CrossRefPubMedGoogle Scholar
  18. Niemi M, Backman JT, Granfors M, Laitila M, Neuvonen M, Neuvonen PJ (2003) Diabetologia 46:1319–1323CrossRefPubMedGoogle Scholar
  19. Niemi M, Backman JT, Neuvonen PJ (2004) Clin Pharmacol Ther 76:239–249CrossRefPubMedGoogle Scholar
  20. Lin ZPJ, Desai-Krieger D, Shum L (2004) J Chromatogr B 801:265–272CrossRefGoogle Scholar
  21. Muxlow AM, Fowles S, Russell P (2001) J Chromatogr B 752:77–84Google Scholar
  22. Mamidi RNVS, Chaluvadi MR, Benjamin B, Ramesh M, Katneni K, Babu AP, Bhanduri J, Rao NMU, Rajagopalan R (2002) Arzneim Forsch Drug Res 52:560–564Google Scholar
  23. Hruska MW, Frye RF (2004) J Chromatogr B 803:317–320CrossRefGoogle Scholar
  24. Mamidi RNVS, Benjamin B, Ramesh M, Srinivas NR (2003) Biomed Chromatogr 17:417–420.CrossRefPubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn/GWV Fachverlage GmbH 2005

Authors and Affiliations

  1. 1.Institute of Public Health, Clinical PharmacologyUniversity of Southern DenmarkOdenseDenmark

Personalised recommendations